Bioterrorism

Total Page:16

File Type:pdf, Size:1020Kb

Bioterrorism BIOTERRORISM Edited by Stephen A. Morse Bioterrorism Edited by Stephen A. Morse Published by InTech Janeza Trdine 9, 51000 Rijeka, Croatia Copyright © 2012 InTech All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. As for readers, this license allows users to download, copy and build upon published chapters even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Publishing Process Manager Sasa Leporic Technical Editor Teodora Smiljanic Cover Designer InTech Design Team First published March, 2012 Printed in Croatia A free online edition of this book is available at www.intechopen.com Additional hard copies can be obtained from [email protected] Bioterrorism, Edited by Stephen A. Morse p. cm. ISBN 978-953-51-0205-2 Contents Preface VII Chapter 1 Current Methods for Detecting the Presence of Botulinum Neurotoxins in Food and Other Biological Samples 1 Luisa W. Cheng, Kirkwood M. Land and Larry H. Stanker Chapter 2 Detection of Bacillus Spores by Surface-Enhanced Raman Spectroscopy 17 Stuart Farquharson, Chetan Shende, Alan Gift and Frank Inscore Chapter 3 Staphylococcal Enterotoxins, Stayphylococcal Enterotoxin B and Bioterrorism 41 Martha L. Hale Chapter 4 Diagnostic Bioterrorism Response Strategies 65 Rickard Knutsson Chapter 5 Recent Advancement in the Development of Vaccines Against Y. pestis – A Potential Agent of Bioterrorism 83 Riyasat Ali and D.N. Rao Chapter 6 Botulinum Neurotoxins 107 Robert P. Webb, Virginia I. Roxas-Duncan and Leonard A. Smith Chapter 7 Ricin Perspective in Bioterrorism 133 Virginia I. Roxas-Duncan and Leonard A. Smith Chapter 8 Spatio-Temporal Disease Surveillance 159 Ross Sparks, Sarah Bolt and Chris Okugami Chapter 9 Rickettsia and Rickettsial Diseases 179 Xue-jie Yu and David H. Walker Preface Pathogenic microorganisms and their toxins have always posed a significant threat to humans, animals, and plants that become exposed and infected naturally. But now there is a newly recognized threat – the deliberate use of pathogenic microorganisms and toxins as weapons in acts of bioterrorism or in the commission of biocrimes. Long before the germ theory of disease was understood, man knew that pathogenic microorganisms and toxins were useful as weapons. However, as the twentieth century came to a close, the perceived difficulties in production, weaponization, and deployment of these biological weapons as well as a belief that moral restraints would preclude the use of these weapons gave many a false sense of security. Recently, a number of events have served to focus attention on the threat of terrorism and the potential for the use of biological weapons against the military, civilian populations, or agriculture for the purpose of causing illness, death, or economic loss. This threat is a significant concern in the United States as well as internationally. Bioterrorist attacks occur as one of two scenarios: overt and covert. In either scenario, biologic agents could be introduced into populations by several routes, including aerosol; contamination of food, water, or medical products; fomites; or the release of infected arthropod vectors. The deliberate nature of such dissemination will often be obvious, as in the case of multiple mailed letters containing anthrax spores (ie overt). Because we currently lack the ability to conduct extensive real-time monitoring for the release of a biologic agent, a covert release of a microorganism of toxin in a population would be likely to go unnoticed for some time, with individuals exposed leaving the attack area before the act of terrorism became evident. Because of the incubation period, the first signs that a microorganism or toxin has been released may not become apparent until hours or weeks later, when individuals become ill and seek medical care. Bioterrorism presents many challenges, particularly when compared to chemical, radiological, or nuclear terrorism. These challenges reflect the dual-use nature of many technologies that can be used for either beneficial purposes or bioterrorism; intentional threats that can coexist with similar and naturally occurring threats; the complexity of the interaction of the threat with the environment, the human immune system, the society/social structure; and rapid advances in biotechnology. Preparing for and responding to bioterrorism in the twenty-first century has brought together diverse VIII Preface disciplines with different backgrounds and cultures, for example intelligence agencies, public health and medical professionals, law enforcement officers, scientists, and the commercial sector. It remains a learning process. Many biological agents can cause illness in humans, but not all are capable of affecting public health and medical infrastructures on a large scale. As part of an effort to focus public health preparedness efforts, the United States Centers for Disease Control and Prevention (CDC) developed a prioritized list of biological agents taking into consideration criteria such as high morbidity and mortality; potential for person-to- person transmission, directly or by vector; low infectious dose and high infectivity by aerosol, with a commensurate ability to cause large outbreaks; ability to contaminate food or water supplies; lack of a specific diagnostic test and/or effective treatment; lack of a safe and effective vaccine; potential to cause anxiety in the general public and in healthcare workers; and potential for weaponization. The final category assignments (A, B, or C) of agents for public health preparedness were based on an overall evaluation of the ratings the agents received in the aforementioned criteria. Agents placed in Category A (eg Yersinia pestis, botulinum neurotoxins) were considered to have a moderate to high potential for large-scale dissemination, the greatest potential for adverse public health impact with mass casualties, and a requirement for broad- based public health preparedness efforts. Agents placed in Category B (eg rickettsia, ricin, staphylococcal enterotoxins) also have some potential for large-scale dissemination with resultant illness, but generally cause less illness and death and, therefore, would be expected to have lower public health and medical impact. Biological agents that were not believed to present a high bioterrorism risk to public health but which could emerge as future threats, as scientific understanding of these agents improved were placed in Category C. This book was written to provide a resource to scientists, epidemiologists, clinicians, and others in the field of bioterrorism defense. Not all possible topics are described. Instead, representative topics, authored by international experts provide a unique and state-of-the-art perspective on this field. The book consists of this preface and nine other chapters that address the broad areas of (1) detection capabilities (ie spatio- temporal disease surveillance; diagnostic bioterrorism response strategies; methods for detecting the presence of botulinum neurotoxins in food and other biological samples; and detection of bacillus spores by surface-enhanced Raman spectroscopy) and (2) characteristics of specific pathogenic microorganisms and toxins (ie Rickettsia and Rickettsial diseases; recent advances in the development of vaccines against Yersinia pestis; botulinum neurotoxins; ricin; and staphylococcal enterotoxins). Dr. Stephen A. Morse Associate Director of Science, Division of Bioterrorism Preparedness and Response, and Director of the Environmental Microbiology Program, CDC, USA 1 Current Methods for Detecting the Presence of Botulinum Neurotoxins in Food and Other Biological Samples Luisa W. Cheng1, Kirkwood M. Land2 and Larry H. Stanker1 Foodborne Contaminants Research Unit, Western Regional Research Center, 1Agricultural Research Service, U.S. Department of Agriculture, Albany, CA, 2Department of Biological Sciences, University of the Pacific, Stockton, CA, USA 1. Introduction Botulinum neurotoxins (BoNTs) are some of the most lethal human bacterial toxins and the causative agent of botulism (Arnon et al., 2001; Simpson, 2004). The usual routes of intoxication for BoNTs are oral ingestion of clostridial spores or pre-formed toxin, manifested as infant, foodborne and adult onset botulism. An increasingly common route of intoxication is associated with intravenous drug use resulting in wound botulism. BoNTs are also classified as Select Agents and have been used as agents of bioterrorism
Recommended publications
  • Assessing Neurotoxicity of Drugs of Abuse
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Assessing Neurotoxicity of Drugs of Abuse 136 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Assessing Neurotoxicity of Drugs of Abuse Editor: Lynda Erinoff, Ph.D. NIDA Research Monograph 136 1993 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT This monograph is based on the papers and discussions from a technical review on “Assessing Neurotoxicity of Drugs of Abuse” held on May 20-21, 1991, in Bethesda, MD. The technical review was sponsored by the National Institute on Drug Abuse (NIDA). COPYRIGHT STATUS NIDA has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Manual of Bacteriology
    m 4-1 /fo3 L CORNELL UNIVERSITY. THE THE GIFT OF ROSWELL P. FLOWER FOR THE USE OF THE N. Y. STATE VETERINARY COLLEGE ,,,. ^ 1897 8394-1 v3 Cornell University Library OR 41.M95 1903 Manual of bacteriology, 3 1924 000 225 965 Cornell University Library The original of tiiis book is in tine Cornell University Library. There are no known copyright restrictions in the United States on the use of the text. http://www.archive.org/details/cu31924000225965 MANUAL OF BACTERIOLOGY \ > rhe?yi><^- MANUAL OF BACTERIOLOGY BY ROBERT MUIR; M.A., M.D., F.R.C.P.Ed. PROFESSOR OF PATHOLOGY, UNIVERSITY OF GLASGOW, AND JAMES RITCHIE, M.A., M.D., B.Sc. T READER IN PATHOLOGY, UNIVERSITY OF OXFORD, AMERICAN EDITION (WITH ADDITIONS), REVISED AND EDITED FROM THE THIRD ENGLISH EDITION BY NORMAN MAC LEOD HARRIS, M.B. (Tor.) ASSOCIATE IN BACTERIOLOGY, THE JOHNS HOPKINS UNIVERSITY, BALTIMQRE. WITH ONE HUND/t^D &= i^ENlPC^LLUSTRATIONS. LIBRARY. THE MACMILLAN COMPANY. LONDON: MACMILLAN & CO., Ltd. 1903 T Jill rights reserved. -7 . "^ '%C; No. X5 G^ Copyright, 1903, By the macmillan company. Set up and electrotyped February, 1903. Norivood Press J. S. Cushing & Co. — Berwick & Smith Norwood, Mass., U.S.A. PREFACE TO THE AMERICAN EDITION. In presenting this the American edition of the well-known and appreciated work of Doctors Muir and Ritchie, the en- deavour has been made to add to the value of the book by giving adequate expression to the best in American laboratory methods and research, and, at the same time, to augment the general scope of the work -without eliminating the personal impress of the authors.
    [Show full text]
  • The Science of the Bioeconomy
    The science of the Bioeconomy Dr. Henrike Gebhardt 05 December 2014 Our positioning Evonik is the creative industrial group from Germany and one of the world’s leading specialty chemicals companies. The Science of the Bioeconomy Page 3 Our credo The Bioeconomy is one driver to promote a more resource-efficient and sustainable economy. Industrial biotechnology is a key technology for realising the bioeconomy. The Science of the Bioeconomy Page 5 Overview Bioeconomy Biotechnology Genetic engineering The Science of the Bioeconomy Page 6 Definitions Bioeconomy Production of renewable biological resources and the conversion of these resources and waste streams into value added products, such as food, feed, and other industrial products and energy. COM(2012) 60, EU Commission, mod. Bio-basedBiotechnology products ProductsThe use whollyof living or organisms partly derived or their from components biomass. EN to16575 make products. Genetic engineering Any of various applications of biological science used in the manipulation of the genome of an organism The Science of the Bioeconomy Page 7 Bio-based products offered by Evonik Polyamids Polyesters VESTAMID ®Terra DYNACOLL ®Terra DYNAPOL ®Terra VISIOMER ®Terra Additives Amino acids Cosmetics BioMTBE Feed additives Health – purified TEGOSOFT ®MM bio-based AdditivesCleaning Health VISCOPLEX ® Series 10 Esterquats RESOMER ® bio- degradable The Science of the Bioeconomy Page 8 Evonik invests in high-growth chemical megatrends Lighthouse investment projects Lysine Russia Consumer Specialties China C4 Chemistry H O / HPPO Europe 2 2 Lysine Expansion China USA Crosslinkers, Isophorone China Consumer Specialties Superabsorbents Brazil Saudi Arabia Methionine Singapore Biodiesel catalysts Argentina Bioeconomy Lysine Traditional Brazil The Science of the Bioeconomy Page 9 Bioeconomy Press releases Company Raw Intermediate Product Material Date of Issue Volume Commissioning DSM/POET (USA) Cellulosics Ethanol Biofuels from corn Jan 2012 90 kta H1.2014 cobs Purac/BASF (ES) Cellulosics Succinic acid e.
    [Show full text]
  • Host-Pathogen Interactions of Secreted and Surface Staphylococcus Aureus Factors
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2010 Host-pathogen interactions of secreted and surface Staphylococcus aureus factors Vanessa Vazquez Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biochemistry Commons, and the Microbiology Commons Recommended Citation Vazquez, Vanessa, "Host-pathogen interactions of secreted and surface Staphylococcus aureus factors" (2010). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 25. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/25 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. Host-pathogen interactions of secreted and surface Staphylococcus aureus factors by Vanessa Vazquez, B.S. APPROVED: Supervisory Professor Magnus Höök, Ph.D. Burton Dickey, M.D. Theresa Koehler, Ph.D. C. Wayne Smith, M.D. Yi Xu, Ph.D. APPROVED: Dean, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences HOST-PATHOGEN INTERACTIONS OF SECRETED AND SURFACE STAPHYLOCOCCUS AUREUS FACTORS A Dissertation Presented to the Faculty of The University of Texas Health Science Center at Houston and The University of Texas M.D.
    [Show full text]
  • Poisoning by Medical Plants
    ARCHIVES OF ArchiveArch Iran Med.of SID February 2020;23(2):117-127 IRANIAN http www.aimjournal.ir MEDICINE Open Systematic Review Access Poisoning by Medical Plants Mohammad Hosein Farzaei, PhD1; Zahra Bayrami, PhD2; Fatemeh Farzaei, PhD1; Ina Aneva, PhD3; Swagat Kumar Das, PhD4; Jayanta Kumar Patra, PhD5; Gitishree Das, PhD5; Mohammad Abdollahi, PhD2* 1Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran 2Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran 3Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria, Bulgaria 4Department of Biotechnology, College of Engineering and Technology, BPUT, Bhubaneswar 751003, Odisha, India 5Research Institute of Biotechnology & Medical Converged Science, Dongguk University-Seoul, Goyangsi 10326, Republic of Korea Abstract Background: Herbal medications are becoming increasingly popular with the impression that they cause fewer side effects in comparison with synthetic drugs; however, they may considerably contribute to acute or chronic poisoning incidents. Poison centers receive more than 100 000 patients exposed to toxic plants. Most of these cases are inconsiderable toxicities involving pediatric ingestions of medicinal plants in low quantity. In most cases of serious poisonings, patients are adults who have either mistakenly consumed a poisonous plant as edible or ingested the plant regarding to its medicinal properties for therapy or toxic properties for illegal aims. Methods: In this article, we review the main human toxic plants causing mortality or the ones which account for emergency medical visits. Articles addressing “plant poisoning” in online databases were listed in order to establish the already reported human toxic cases.
    [Show full text]
  • International Handbook of Foodborne Pathogens
    INTERNATIONAL HANDBOOK OF FOODBORNE PATHOGENS EDITED BY MARIANNE D. MILIOTIS U.S. Food and Drug Administration College Park, Maryland, U.S.A. JEFFREY W. BIER Food Safety Consultant Alexandria, Virginia, U.S.A. MARCEL H MARCEL DEKKER, INC. NEW YORK • BASEL Copyright 2003 by Marcel Dekker, Inc. All Rights Reserved. Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress. ISBN: 0-8247-0685-4 This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc. 270 Madison Avenue, New York, NY 10016 tel: 212-696-9000; fax: 212-685-4540 Eastern Hemisphere Distribution Marcel Dekker AG Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland tel: 41-61-260-6300; fax: 41-61-260-6333 World Wide Web http://www.dekker.com The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above. Copyright 2003 by Marcel Dekker, Inc. All Rights Reserved. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher. Current printing (last digit): 10987654321 PRINTED IN THE UNITED STATES OF AMERICA Copyright 2003 by Marcel Dekker, Inc. All Rights Reserved. FOOD SCIENCE AND TECHNOLOGY A Series of Monographs, Textbooks, and Reference Books EDITORIAL BOARD Senior Editors Owen R. Fennema University of Wisconsin-Madison Y. H. Hui Science Technology System Marcus Karel Rutgers University (emeritus) Pieter Walstra Wagenmgen University John R.
    [Show full text]
  • Biosafety Level 1 and Rdna Training
    Biosafety Level 1and rDNA Training Office of Biological Safety Biosafety Level 1 and rDNA Training • Difference between Risk Group and Biosafety Level • NIH and UC policy on recombinant DNA • Work conducted at Biosafety Level 1 • UC Code of Conduct for researchers Biosafety Level 1 and rDNA Training What is the difference between risk group and biosafety level? Risk Groups vs Biosafety Level • Risk Groups: Assigned to infectious organisms by global agencies (NIH, CDC, WHO, etc.) • In US, only assigned to human pathogens (NIH) • Biosafety Level (BSL): How the organisms are managed/contained (increasing levels of protection) Risk Groups vs Biosafety Level • RG1: Not associated with disease in healthy adults (non‐pathogenic E. coli; S. cerevisiae) • RG2: Cause diseases not usually serious and are often treatable (S. aureus; Legionella; Toxoplasma gondii) • RG3: Serious diseases that may be treatable (Y. pestis; B. anthracis; Rickettsia rickettsii; HIV) • RG4: Serious diseases with no treatment/cure (Hemorrhagic fever viruses, e.g., Ebola; no bacteria) Risk Groups vs Biosafety Level • BSL‐1: Usually corresponds to RG1 – Good microbiological technique – No additional safety equipment required for biological work (may still need chemical/radiation protection) – Ability to destroy recombinant organisms (even if they are RG1) Risk Groups vs Biosafety Level • BSL‐2: Same as BSL‐1, PLUS… – Biohazard signs – Protective clothing (lab coat, gloves, eye protection, etc.) – Biosafety cabinet (BSC) for aerosols is recommended but not always required – Negative airflow into room is recommended, but not always required Risk Groups vs Biosafety Level • BSL‐3: Same as BSL‐2, PLUS… – Specialized clothing (respiratory protection, Tyvek, etc.) – Directional air flow is required.
    [Show full text]
  • Fibrinogen Binding Sites P336 and Y338 of Clumping Factor a Are Crucial for Staphylococcus Aureus Virulence
    Fibrinogen Binding Sites P336 and Y338 of Clumping Factor A Are Crucial for Staphylococcus aureus Virulence Elisabet Josefsson1*, Judy Higgins2, Timothy J. Foster2, Andrej Tarkowski1 1 Department of Rheumatology and Inflammation Research, University of Gothenburg, Go¨teborg, Sweden, 2 Microbiology Department, Moyne Institute of Preventive Medicine, Trinity College, Dublin, Ireland Abstract We have earlier shown that clumping factor A (ClfA), a fibrinogen binding surface protein of Staphylococcus aureus,isan important virulence factor in septic arthritis. When two amino acids in the ClfA molecule, P336 and Y338, were changed to serine and alanine, respectively, the fibrinogen binding property was lost. ClfAP336Y338 mutants have been constructed in two virulent S. aureus strains Newman and LS-1. The aim of this study was to analyze if these two amino acids which are vital for the fibrinogen binding of ClfA are of importance for the ability of S. aureus to generate disease. Septic arthritis or sepsis were induced in mice by intravenous inoculation of bacteria. The clfAP336Y338 mutant induced significantly less arthritis than the wild type strain, both with respect to severity and frequency. The mutant infected mice developed also a much milder systemic inflammation, measured as lower mortality, weight loss, bacterial growth in kidneys and lower IL-6 levels. The data were verified with a second mutant where clfAP336 and Y338 were changed to alanine and serine respectively. When sepsis was induced by a larger bacterial inoculum, the clfAP336Y338 mutants induced significantly less septic death. Importantly, immunization with the recombinant A domain of ClfAP336SY338A mutant but not with recombinant ClfA, protected against septic death.
    [Show full text]
  • Clinical Laboratory Preparedness and Response Guide
    TABLE OF CONTENTS Table of Contents ...................................................................................................................................................................................... 2 State Information ....................................................................................................................................................................................... 7 Introduction .............................................................................................................................................................................................. 10 Laboratory Response Network (LRN) .......................................................................................................................................... 15 Other Emergency Preparedness Response Information: .................................................................................................... 19 Radiological Threats ......................................................................................................................................................................... 21 Food Safety Threats .......................................................................................................................................................................... 25 BioWatch Program ............................................................................................................................................................................ 27 Bio Detection Systems
    [Show full text]
  • Chapter 26 BIOSAFETY Appendix B. Pathogen and Toxin Lists B.1
    Chapter 26 BIOSAFETY ____________________ Appendix B. Pathogen and Toxin Lists B.1 Introduction and Scope Pathogens and toxins are discussed in detail in Work Process B.3.d, Pathogenic Agents and Toxins, of this manual. This appendix lists the following biological agents and toxins presented in Work Process B.3.d: Human etiologic agents (pathogens) from Appendix B of the NIH Guidelines Select agents and toxins from the National Select Agent Registry (NSAR) Plant pathogens previously identified by U.S. Department of Agriculture (USDA) These lists are provided for convenience in this manual, but may not reflect the actual regulatory list or applicable agents or materials. Regulatory sources, standards, and Web links noted in this appendix and Work Process B.3.d should be consulted to confirm applicable agents or toxins. B.2 NIH Guidelines Human Etiologic Agents This section provides a list of human pathogens and their Risk Group (RG) 2, RG3, and RG4 designations as excerpted from Appendix B, Classification of Human Etiologic Agents on the Basis of Hazard, of the NIH Guidelines, amendment effective November 6, 2013. B.2.1 Risk Group 1 Agents RG1 agents are not associated with disease in healthy adult humans. Examples of RG1 agents include asporogenic Bacillus subtilis or Bacillus licheniformis (see NIH Guidelines, Appendix C-IV-A, Bacillus subtilis or Bacillus licheniformis Host-Vector Systems, Exceptions); adeno-associated virus (AAV, all serotypes); and recombinant or synthetic AAV constructs, in which the transgene does not encode either a potentially tumorigenic gene product or a toxin molecule and which are produced in the absence of a helper virus.
    [Show full text]
  • Denotations & Old Terminologies Used in Homopathy
    Denotations & Old terminologies used in Homopathy Dr Jagathy Murali. Kerala Majority of the students and practitioners in Homeopathy experiencing great difficulty in understanding the meaning of old terminologies in various repertories and materia medicas. Hence this is an attempt to lessen the difficulties of practitioners and students. Acetonemia The presence of acetone bodies in relativly large amounts in blood,manifested at first by erethism,later by progressive depression Acne An inflammatory follucular,papular and pustular eruption involving the sebaceous apparatus Acne rosacea Rosasea;a chronic disease of the skin of the nose,forehead,and cheecks,marked by flushing,followed by red colouration due to dilatation of the capillaries,with the appearance of papules and acne like pustules. Acne simplex Acne vulgaris Acrid Sharp,pungent,biting,irritating Actinomycosis An infectious disease caused by actinomyces,marked by indolent inflammatory lesions of the lymph nodes draining the mouth,by inatraperitonial abcess,or by lung abcess due to aspiration. Adenitis Inflammation of a lymph node or of a gland Adenoid vegetations The adenoids, which spring from the vault of the pharynx, form masses varying in size from a small pea to an almond. They may be sessile, with broad bases, or pedunculated. They are reddish in color, of moderate firmness, and contain numerous blood-vessels. "abundant, as a rule, over the vault, on a line with the fossa of the eustachian tube, the growths may lie posterior to the fossa namely, in the depression known as the fossa of rosenmuller, or upon the parts which are parallel to the posterior wall of the pharynx.
    [Show full text]
  • Biosafety Manual 2017
    Biosafety Manual 2017 Revised 6/2017 Policy Statement It is the policy of Northern Arizona University (NAU) to provide a safe working environment. The primary responsibility for insuring safe conduct and conditions in the laboratory resides with the principal investigator. The Office of Biological Safety is committed to providing up-to-date information, training, and monitoring to the research and biomedical community concerning the safe conduct of biological, recombinant, and acute toxin research and the handling of biological materials in accordance with all pertinent local, state and federal regulations, guidelines, and laws. To that end, this manual is a resource, to be used in conjunction with the CDC and NIH guidelines, the NAU Select Agent Program, Biosafety in Microbiological and Biomedical Laboratories (BMBL), and other resource materials. Introduction This Biological Safety Manual is intended for use as a guidance document for researchers and clinicians who work with biological materials. It should be used in conjunction with the Laboratory-Specific Safety Manual, which provides more general safety information. These manuals describe policies and procedures that are required for the safe conduct of research at NAU. The NAU Personnel Policy on Safety 5.03 also provides guidance for safety in the workplace. Responsibilities In the academic research/teaching setting, the principal investigator (PI) is responsible for ensuring that all members of the laboratory are familiar with safe research practices. In the clinical laboratory setting, the faculty member who supervises the laboratory is responsible for safety practices. Lab managers, supervisors, technicians and others who provide supervisory roles in laboratories and clinical settings are responsible for overseeing the safety practices in laboratories and reporting any problems, accidents, and spills to the appropriate faculty member.
    [Show full text]